CARE Ratings Ltd
CARE Ratings Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #19 of 22 in Capital Markets
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
1 of 3 strong
The short version
CARE Ratings expects to continue outpacing overall industry growth in domestic ratings, particularly leveraging faster growth in mid-corporates and bank loan segments. FY26 showed strong quality-led performance with broad-based growth and 24% YoY PAT growth; EPS growth is implied from all-time high PAT of INR173.69 crores.
From CARE Ratings Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- CARE Ratings expects to continue outpacing overall industry growth in domestic ratings, particularly leveraging faster growth in mid-corporates and bank loan segments.
- Non-rating segments like CareEdge Analytics (with EdgeAvira.AI platform) are approaching breakeven and aim to scale recurring revenue through long sales cycles and client retention.
- Advisory business, especially sustainability and ESG advisory, is growing steadily with good margins and expanding client base.
- International operations' growth depends on the development stage of debt markets in respective geographies; fast-growing markets offer faster traction.
2 more points from CARE Ratings Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what CARE Ratings Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- CARE Ratings Limited is currently holding cash on its balance sheet and remains open to strategic inorganic acquisitions that fit their core domains of credit risk, analytics, and consulting services.
- Their acquisition strategy is disciplined, seeking targets offering strategic fit, foothold in adjacent areas or geographies, and valuations reflecting intrinsic value, avoiding speculative premiums.
- No recent acquisitions have materialized due to valuation challenges and a focus on stabilizing and turning around existing subsidiaries first.
- The company has achieved breakeven in key subsidiaries (e.g., CAAPL), positioning them better to integrate acquisitions without management distraction.
2 more points from CARE Ratings Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Capital Markets
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what CARE Ratings Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what CARE Ratings Ltd said on order book & pipeline — free account, 30 seconds.
CARE Ratings Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹112 Cr, net profit ₹33 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What CARE Ratings's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
- Q4 FY20 earnings call →
- Q2 FY20 earnings call →
- Q1 FY20 earnings call →
- Q4 FY19 earnings call →
Others in Capital Markets this season
- Emk.Global Fin. (Q4 FY26)
Q4 FY26 Revenue from Operations: INR 1,484 million, up 109% YoY from INR 710 million in Q4 FY25 (Page 34). Key concall takeaways from Emkay Global Financial…
- Systematix Corporate Services Ltd (Q4 FY26)
Revenue from operations for Q4 FY26: ₹23.50 Cr . Key concall takeaways from Systematix Corporate Services Ltd's Q4 FY26 earnings call — and how it ranks…
- Dam Capital Advisors Ltd (Q4 FY26)
Quarterly Revenue (Q4 FY26):** ₹29.3 Cr vs. Key concall takeaways from Dam Capital Advisors Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
- Indian Energy Ex (Q4 FY26)
FY26 electricity volume rose 17% YoY to 141 billion units, with RTM volumes growing 41% and green market volumes up 23% YoY, indicating strong growth momentum…
Potential multibaggers · Q2 FY27
Potential multibaggers in Capital Markets
on management's own guidance
- Nippon Life Ind.Good growth2
- BSEGood growth1
- Motil.Oswal.Fin.Good growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
CARE Ratings Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were CARE Ratings Ltd Q4 FY26 results?
CARE Ratings expects to continue outpacing overall industry growth in domestic ratings, particularly leveraging faster growth in mid-corporates and bank loan segments. FY26 showed strong quality-led performance with broad-based growth and 24% YoY PAT growth; EPS growth is implied from all-time high PAT of INR173.69 crores.
What is CARE Ratings Ltd share price analysis?
CARE Ratings Ltd currently shows a below-average growth signal. The stock trades at a P/E of 30.7 with a market cap of ₹5,263 Cr. Investors should review the full earnings analysis for detailed insights.
Is CARE Ratings Ltd planning capital expenditure?
CARE Ratings Limited is currently holding cash on its balance sheet and remains open to strategic inorganic acquisitions that fit their core domains of credit risk, analytics, and consulting services.
Keep CARE Ratings Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.